Worth reading
69In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2026 · Six months (cumulative) and full yearNet Sales—→—Millions of yen
—
Operating profit—→—Millions of yen
—
Profit attributable to owners of the parent—→—Millions of yen
—
Net income per share—→—yen and sen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
医薬品事業は、薬価改定や「ビダーザ」の後発品の影響はあるものの、新製品群や「ウプトラビ」の海外売上に伴うロイヤリティ収入の伸長等により増収を見込む。機能食品事業は、新製品開発・投入と重点品目への取り組み強化により増収を見込む。
Previous-period results2025年３月期：売上収益160,232百万円、営業利益35,450百万円、税引前利益36,135百万円、親会社の所有者に帰属する当期利益32,558百万円、基本的１株当たり当期利益483.40円
Dividend forecast revision2026年３月期は中間配当1株62円、期末配当1株62円、年間124円を予定。配当予想の修正に関する明示はNot disclosed。
Consolidated / non-consolidatedConsolidated and non-consolidated (standalone)
| Item | Details |
|---|---|
| Net Sales | Not disclosed → Second quarter (cumulative) 81,500 / Full year 173,000 |
| Operating profit | Not disclosed → Second quarter (cumulative) 16,000 / Full year 30,000 |
| Profit attributable to owners of the parent | Not disclosed → Second quarter (cumulative) 12,800 / Full year 24,000 |
| Net income per share | Not disclosed → Second quarter (cumulative) 189.97 / Full year 356.20 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Six months (cumulative) and full year |
| Previous-period results | 2025年３月期：売上収益160,232百万円、営業利益35,450百万円、税引前利益36,135百万円、親会社の所有者に帰属する当期利益32,558百万円、基本的１株当たり当期利益483.40円 |
| Reason for the revision | 医薬品事業は、薬価改定や「ビダーザ」の後発品の影響はあるものの、新製品群や「ウプトラビ」の海外売上に伴うロイヤリティ収入の伸長等により増収を見込む。機能食品事業は、新製品開発・投入と重点品目への取り組み強化により増収を見込む。 |
| Dividend forecast revision | 2026年３月期は中間配当1株62円、期末配当1株62円、年間124円を予定。配当予想の修正に関する明示はNot disclosed。 |
| Consolidated / non-consolidated | Consolidated and non-consolidated (standalone) |
Items this document does not state (3)
Ordinary incomePublication date of previous forecastDetails and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医薬品事業では、「Deramiocel」「ビキセオス」「フィンテプラ」「ウプトラビ」などの新製品群や「ウプトラビ」の海外売上に伴うロイヤリティ収入の伸長により増収を見込んでいる。機能食品事業では、新製品の開発・投入と重点品目への取り組み強化により増収を見込んでいる。次期の利益が前期実績を下回る理由は、本文では明示されていない。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.